Literature DB >> 14968433

The novel Ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro.

Robert A McPherson1, Mark C Conaway, Chris W Gregory, Wei Yue, Richard J Santen.   

Abstract

BACKGROUND: The majority of men with advanced prostate cancer (PCa) respond to androgen deprivation therapy (ADT) with objective evidence of tumor regression. However, these tumors will regrow in the presence of low-androgen levels after 12-18 months. Regrowth after ADT is associated with upregulation of growth factor (GF) mediated pathways. The compound farnesylthiosalicylate (FTS), a specific antagonist of the 21 kDa Ras protein, suppresses GF signaling and it might be a useful therapy against advanced PCa.
METHODS: We measured androgen and GF dependent growth of androgen dependent LNCaP and androgen hypersensitive CWR-R1 PCa cells in response to specific inhibitors of GF pathways, including FTS. Inhibition of GF mediated signaling and cell-cycle pathways was confirmed by Western blotting of extracts from treated cells.
RESULTS: Both LNCaP and CWR-R1 cells were dependent on GF signaling pathways for cell growth. FTS, as well as suppressing cell growth, inhibited GF signaling pathway activity and reduced the levels of E2F1, p-Rb, and p-cdc2, all GF dependent mediators of cell-cycle progression.
CONCLUSIONS: These data suggest that FTS might be a useful agent against PCa that has relapsed after ADT. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14968433     DOI: 10.1002/pros.10336

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  10 in total

1.  RasGRP3 contributes to formation and maintenance of the prostate cancer phenotype.

Authors:  Dazhi Yang; Noemi Kedei; Luowei Li; Juan Tao; Julia F Velasquez; Aleksandra M Michalowski; Balázs I Tóth; Rita Marincsák; Attila Varga; Tamás Bíró; Stuart H Yuspa; Peter M Blumberg
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

2.  Combined effect of protein kinase B inhibitor or extracellular signal-regulated kinase inhibitor against farnesyltransferase inhibition-induced apoptosis in SiHa cells.

Authors:  Sun Joo Lee; Chung Soo Lee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-10-15       Impact factor: 3.000

3.  Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling.

Authors:  A H Palamakumbura; S R Vora; M A Nugent; K H Kirsch; G E Sonenshein; P C Trackman
Journal:  Oncogene       Date:  2009-07-13       Impact factor: 9.867

4.  Targeted delivery of curcumin to tumors via PEG-derivatized FTS-based micellar system.

Authors:  Yichao Chen; Xiaolan Zhang; Jianqin Lu; Yixian Huang; Jiang Li; Song Li
Journal:  AAPS J       Date:  2014-04-05       Impact factor: 4.009

5.  Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics.

Authors:  Liwei Lang; Chloe Shay; Xiangdong Zhao; Yong Teng
Journal:  J Exp Clin Cancer Res       Date:  2017-08-23

6.  Celecoxib combined with salirasib strongly inhibits pancreatic cancer cells in 2D and 3D cultures.

Authors:  Dongli Li; Yuran Ma; Wenfeng Liu; Xiang Ren; Min Chen; Xuetao Xu; Zhaojun Sheng; Kun Zhang; Renping Zhou; Susan Goodin; Xi Zheng
Journal:  Int J Med Sci       Date:  2020-07-09       Impact factor: 3.738

Review 7.  Drugging the Small GTPase Pathways in Cancer Treatment: Promises and Challenges.

Authors:  Néstor Prieto-Dominguez; Christopher Parnell; Yong Teng
Journal:  Cells       Date:  2019-03-16       Impact factor: 6.600

8.  Disrupting the oncogenic synergism between nucleolin and Ras results in cell growth inhibition and cell death.

Authors:  Sari Schokoroy; Dolly Juster; Yoel Kloog; Ronit Pinkas-Kramarski
Journal:  PLoS One       Date:  2013-09-24       Impact factor: 3.240

9.  Ras inhibition enhances autophagy, which partially protects cells from death.

Authors:  Eran Schmukler; Efrat Grinboim; Sari Schokoroy; Adva Amir; Eya Wolfson; Yoel Kloog; Ronit Pinkas-Kramarski
Journal:  Oncotarget       Date:  2013-01

10.  Chloroquine synergizes with FTS to enhance cell growth inhibition and cell death.

Authors:  Eran Schmukler; Eya Wolfson; Roni Haklai; Galit Elad-Sfadia; Yoel Kloog; Ronit Pinkas-Kramarski
Journal:  Oncotarget       Date:  2014-01-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.